Life expectancy of people living with HIV (PLWH) is now close to that of the HIV-uninfected
population. As a result, age-related comorbidities, including osteoporosis, are increasing in …

Globally, the number of new HIV infections remains unacceptably high, and urgent new
approaches are needed to advance HIV vaccine science. However, the development of a …

We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred
nine individuals with this variant had a 0.54 to 0.74 log10 increase (ie, a~ 3.5-fold to 5.5-fold …

Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here,
we trace the development of these autoantibodies at high-resolution using longitudinal …

Background The efficacy and tolerability of long-acting cabotegravir and rilpivirine were
demonstrated in Phase III trials. However, low concentrations combined with other risk …

Background Integrase strand transfer inhibitors (INSTIs) have been associated with an
increased risk for cardiovascular disease (CVD) events. We investigated the impact of …

Background Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV)
incidence through a" treatment as prevention"(TasP) effect. We assessed changes in …

Background Advancements in access to antiretroviral therapy (ART) and human
immunodeficiency virus (HIV) care have led to a decline in AIDS-related deaths among …

Background Starting combination antiretroviral therapy (cART) during primary human
immunodeficiency virus type 1 (HIV-1) infection results in a smaller HIV-1 latent reservoir …

Abstract Background The Swiss HCVree Trial (NCT 02785666) was conducted in 2015–
2017 with the goal of implementing a population-based systematic hepatitis C virus (HCV) …